MarkPap India, LLC
MPI holds patents for mass pap smear screening, the best prevention from cervical cancer, not attainable for India. One million is needed.
MarkPap India, LLC (MPI) was incorporated to sell BioSciCon's MarkPap(r) technology tools for cervical cancer prevention to Indian distributors, which will enable Indian healthcare providers to reverse negative trends of increasing cervical cancer prevalence and mortality into self-sustainable positive trends, making crucial impact on Indian women's health, while earning revenue from sales. Equity investment and licensing are welcome